These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34840217)

  • 21. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
    Yang AY
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
    Aksenov S; Peck CC; Eriksson UG; Stanski DR
    Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29488355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors influencing the occurrence of hyperuricemia and poor cardiac and renal outcomes in chronic kidney disease.
    Liu WW; Yang GB; Liu ZY; Guo Y; Duan LX; Yuan JH; Liao L; Zhang CF; Lu JR; Hu J; Chen J
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):342-349. PubMed ID: 38235885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
    Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
    Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
    Tsuruta Y; Mochizuki T; Moriyama T; Itabashi M; Takei T; Tsuchiya K; Nitta K
    Clin Rheumatol; 2014 Nov; 33(11):1643-8. PubMed ID: 25048744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
    Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
    Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
    Oh TR; Choi HS; Kim CS; Bae EH; Ma SK; Sung SA; Kim YS; Oh KH; Ahn C; Kim SW
    Sci Rep; 2019 Apr; 9(1):6681. PubMed ID: 31040373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
    Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
    Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
    Kose E; An T; Kikkawa A; Matsumoto Y; Hayashi H
    Biol Pharm Bull; 2014; 37(2):226-31. PubMed ID: 24492719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
    Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.
    Yamaguchi A; Harada M; Yamada Y; Hashimoto K; Kamijo Y
    BMC Nephrol; 2017 May; 18(1):162. PubMed ID: 28521802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
    Tsukamoto S; Okami N; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
    Clin Rheumatol; 2022 Mar; 41(3):911-919. PubMed ID: 34642880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project.
    Russo E; Viazzi F; Pontremoli R; Barbagallo CM; Bombelli M; Casiglia E; Cicero AFG; Cirillo M; Cirillo P; Desideri G; D'Elia L; Ferri C; Galletti F; Gesualdo L; Giannattasio C; Iaccarino G; Leoncini G; Mallamaci F; Maloberti A; Masi S; Mengozzi A; Mazza A; Muiesan ML; Nazzaro P; Palatini P; Parati G; Rattazzi M; Rivasi G; Salvetti M; Tikhonoff V; Tocci G; Ungar A; Verdecchia P; Virdis A; Volpe M; Grassi G; Borghi C;
    J Nephrol; 2022 Jan; 35(1):211-221. PubMed ID: 33755930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
    Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
    J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
    Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
    Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.